Results 161 to 170 of about 227,142 (341)

A Drosophila model of prion disease and its metabolic changes in the brain

open access: yesAnimal Models and Experimental Medicine, EarlyView.
We developed a Drosophila model for prion disease, and flies were capable of expressing the hamster prion protein (HaPrP) under the control of the GAL4/UAS system. The model exhibited some characteristics of the disease in mammals and displayed alterations in protein, sphingolipid, and carbohydrate metabolism. Preliminary applications have demonstrated
Dongdong Wang   +14 more
wiley   +1 more source

Enhancement of developmental defects in the boron‐deficient maize mutant tassel‐less1 by reduced auxin levels

open access: yesJournal of Plant Nutrition and Soil Science, EarlyView., 2023
Abstract Background Plant responses to deficiencies of the micronutrient boron are diverse and go beyond the well‐characterized function of boron in cell wall crosslinking. To explain these phenotypic discrepancies, hypotheses about interactions of boron with various phytohormones have been proposed, particularly auxin.
Michaela S. Matthes   +3 more
wiley   +1 more source

An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene.

open access: bronze, 1990
H. Rosenbaum   +6 more
openalex   +1 more source

Comparative analysis of two newly established Cre rat lines, NeuN‐Cre and Thy1‐Cre, for neurological research

open access: yesAnimal Models and Experimental Medicine, EarlyView.
We generated two neuron‐specific Cre rat lines, Thy1‐Cre and NeuN‐Cre, using CRISPR/Cas9‐mediated targeted insertion. Both lines were validated for high neural specificity by crossing them with a Cre reporter rat. When bred with an ND1 conditional knockout rat, the two Cre lines produced distinct phenotypic outcomes. These rat lines have been deposited
Keru Li   +15 more
wiley   +1 more source

Structured Lipids: Synthesis, Genetic Engineering, and Applications

open access: yesJournal of the American Oil Chemists' Society, EarlyView.
ABSTRACT Lipids are essential to the human body, but some can be harmful. As a result, current research focuses on structured lipids (SLs), which are engineered to have specific fatty acid arrangements. These structural modifications can enhance both nutritional and physical properties.
Chandu S. Madankar   +5 more
wiley   +1 more source

Transgenic [PDF]

open access: yes, 2011
openaire   +1 more source

Optogenetic control of transgene expression in Marchantia polymorpha

open access: yesApplications in Plant Sciences, EarlyView.
Abstract Premise The model liverwort Marchantia polymorpha is an emerging testbed species for plant metabolic engineering but lacks well‐characterized inducible promoters, which are necessary to minimize biochemical and physiological disruption when over‐accumulating target products.
Anya Lillemor Lindström Battle   +1 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

open access: yesThe Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom   +11 more
wiley   +1 more source

Instability of long inverted repeats within mouse transgenes. [PDF]

open access: bronze, 1996
Andrew Collick   +7 more
openalex   +1 more source

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

open access: yesThe Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy